AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...
AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...
LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...
Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination ...
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...